Red light and PBM · human studies first
Plate 40
Wavelength record
What a trial used
27
Sources on the page
6
Device classes
On this page. Counts, not a grade and not a device ranking.
4 of the goals carry the stronger records (mouth sores, hair, knee, neck). A longer list of papers is not a higher certainty. The 2025 umbrella started from 204 randomised trials and still called most endpoints low or very low certainty.
Read this first
Educational use only. This page is not medical advice, not a treatment protocol, and not a personal session plan. Numbers from trials are what a study ran, not a dose for you. MASCC, ISOO, and WALT documents are references for clinicians. They are not do-it-yourself schedules. Aaron Cuha is a coach, not a doctor.
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Photobiomodulation, also called low-level light or low-level laser therapy, is non-heating red or near-infrared light aimed at tissue. Clinics, panels, masks, combs, helmets, and beds can all emit those colors. They are not the same intervention. A contact laser on a joint and a person standing in front of a panel deliver different light to different tissue.
The trials on this page did not share one wavelength. Knee trials that separated from a placebo laser used about 785 to 860 nm, or 904 nm, and they dosed each spot. Exercise trials that reported a benefit mostly sat between 655 and 950 nm. There is no single wavelength on this page that covers every goal.
Lasers and LEDs can both be used as photobiomodulation sources. A 2018 review argues that the light does not have to be a coherent laser beam for the leading biological story to apply. That does not make a consumer LED the same dose as the laser in a trial. Spectrum, distance, and energy still decide what arrives.
The usual story is a hypothesis about mitochondria. It is not a settled switch, and it is not a result in people. The human results are in the next section. This one says what the lab literature proposes, and where that proposal is weak.
Leading hypothesis
A 2016 review lays out the idea most sellers repeat. Red and near-infrared photons are absorbed by cytochrome c oxidase, a protein in the mitochondrial chain that uses oxygen. The proposed follow-on is a shift in nitric oxide, electron flow, ATP, and downstream signals. The authors present that as a proposal, next to other ideas, including light-sensitive ion channels. It is not a clinical trial.
Same cluster, later synthesis
A 2018 review organises the same literature around mitochondrial redox signaling. It is influential, and it comes from the research group most associated with the cytochrome story. Influence is not the same thing as a measurement in people.
Laser versus LED
A 2018 comparison of lasers and LEDs treats coherence as unnecessary for the leading account. Geometry still matters. A comb on the scalp, a mask on the face, and a bed around the body are three doses even when the brochure names the same nanometres.
Cells, animals, and the unresolved gap. Not a human outcome.
Quirk and Whelan went back to the cytochrome c oxidase claim in 2020. They wrote that no reliable demonstration of a light-triggered effect on that enzyme had been reported. Studies were not reproducible, not clearly relevant, or used wavelengths unlikely to matter in living tissue. They argue that nitric oxide, including light-driven release of nitric oxide from the enzyme, may sit closer to the center of the effect. They declared no competing financial interests. On this page the cytochrome story stays a leading hypothesis with that hole in it.
Huang and colleagues updated the biphasic dose story in 2011. In cell and animal work, a middle dose can stimulate and a higher dose can flatten or reverse the effect. ATP and mitochondrial membrane potential in that review follow that two-sided curve. Reactive oxygen species can be more complicated. A mouse brain-injury example in the paper peaks at a middle number of treatments and a middle energy, and misses on either side. That is why more watts is not a plan. The paper does not tell a person how long to stand in front of a panel.
Educational use only. This page is not medical advice, not a treatment protocol, and not a personal session plan. Numbers from trials are what a study ran, not a dose for you. MASCC, ISOO, and WALT documents are references for clinicians. They are not do-it-yourself schedules. Aaron Cuha is a coach, not a doctor.
Each row is a record from a paper. It is not a protocol for you. Joules per spot on a clinic laser are not minutes in front of a panel.
| Goal | Who | What the trial ran | Source |
|---|---|---|---|
| Pattern hair loss | 103 men and 122 women in the efficacy analysis | Named laser combs, whole scalp, three times a week, for 26 weeks. Not a panel, and not a bed. | PMID 24474647 |
| Knee osteoarthritis | Subgroup of placebo-controlled laser trials, 22 trials and 1,063 people in the full pooling | 4 to 8 joules per treatment spot at 785 to 860 nm, or 1 to 3 joules per spot at 904 nm. Clinic laser spots, not minutes in front of a panel. | PMID 31662383 |
| Local muscle performance | Positive trials inside a review of healthy adults. Evidence quality very low to moderate. | Mostly 655 to 950 nm. About 20 to 60 joules on small muscle groups and 60 to 300 joules on large groups, up to 200 milliwatts per diode. | PMID 29090398 |
| Morning near-infrared and sleep | Adults with mild sleep complaints, sham-controlled, four weeks, summer and winter | 6.5 joules per square centimeter in the arm that changed mood and drowsiness in winter. Sleep and circadian measures did not change. | PMID 36671752 |
Stronger records first. Nulls and marketing-ahead goals stay on the same page. Nothing here is ranked against the others as a product, and no device is recommended.
01 · Stronger human record
Who was studied
Adults receiving a stem cell transplant, or radiotherapy to the head and neck with or without chemotherapy. The photobiomodulation guideline is Zadik and colleagues, 2019. The parent mucositis guideline is Elad and colleagues, 2020, covering 1,197 publications on mouth and gut sores, not all of them about light.
The light guideline recommends specific settings to prevent oral mucositis in those cancer-treatment settings, and it says the clinician should follow every parameter of the protocol that was chosen. It could not write a guideline for sores that were already established, or for chemotherapy alone, because the evidence was not good enough. A 2022 WALT position paper on cancer-treatment side effects says it is informational. Commercial employees were barred from the parent guideline panel. Authors of that parent paper disclose industry ties outside the work.
Device class in the evidence
Calibrated intraoral laser or LED, used by a clinician.
What this does not show
That a home panel, a mask, or a whole-body bed is the same treatment. Those oncology settings use intraoral devices and an exact parameter set. A bed session is not that protocol. None of this shows that red light treats cancer.
02 · Stronger human record
Who was studied
Jimenez and colleagues randomised 128 men and 141 women with pattern hair loss to a HairMax laser comb or a sham device. The efficacy analysis kept 103 men and 122 women. Gupta and colleagues later pooled 15 photobiomodulation studies, 795 people, using hair density.
Terminal hair at 26 weeks rose by about 18 to 26 hairs per square centimeter on the laser combs, against about 2 to 9 on the sham devices, depending on the model. The combs were used on the whole scalp three times a week. No serious adverse events were reported in anyone on the comb. The later meta-analysis put the standardised mean difference at 1.02 (interval 0.68 to 1.36) in favor of treatment. Laser-only looked stronger than laser plus LED in that pooling, and the combination still beat control. Comb style versus helmet style was not a clear difference.
Device class in the evidence
Scalp comb, cap, or helmet. Not a whole-body bed.
What this does not show
That any red lamp grows hair, that a bed does, that the gain lasts after the trial, or that light replaces minoxidil or finasteride. The comb result belongs to those devices. FDA clearance of a comb is not a drug approval, and it does not transfer to a panel.
03 · Stronger human record
Who was studied
Stausholm and colleagues pooled 22 randomised placebo-controlled trials, 1,063 people with knee osteoarthritis. In a 2025 umbrella of many conditions, knee osteoarthritis disability was one of the moderate-certainty signals (equivalent standardised mean difference 0.65, interval 0.14 to 1.15).
At the end of therapy, pain was 14.23 mm lower on a 100 mm scale than placebo (interval 7.31 to 21.14). The doses that review treated as the ones that worked were 4 to 8 joules per treatment spot at 785 to 860 nm, and 1 to 3 joules per spot at 904 nm. In that subgroup, pain was 18.71 mm lower at the end of therapy. Disability was also lower. The review reported no adverse events. Two authors are former board members of the World Association for Laser Therapy and said they received no money from it.
Device class in the evidence
Local clinic laser on the knee.
What this does not show
That a panel across the room, or a bed, delivers those joules to the joint. It does not show new cartilage. It does not show that every wavelength works. The joules are what those trials ran. They are not a dose for you.
04 · Stronger human record
Who was studied
Chow and colleagues, Lancet, 2009. 16 randomised trials, 820 people with acute or chronic neck pain. Laser was applied to the painful sites. The review reported no funding.
In 11 trials that used a 100 mm pain scale, intensity fell by 19.86 mm more with laser than with control (interval 10.04 to 29.68). In five chronic-pain trials that counted who improved, the relative risk was 4.05 (interval 2.74 to 5.98). In seven trials with follow-up from 1 to 22 weeks after treatment stopped, pain was still about 22 mm lower. Side effects were mild and not different from placebo.
Device class in the evidence
Local laser to the neck.
What this does not show
A cure, or that a consumer panel or a bed is the same thing as point-dose laser on the neck. Acute and chronic neck pain were not one identical result. The review does not assign you a session length.
05 · Mixed, local, or early
Who was studied
Yeh and colleagues, 9 randomised trials, 325 people with fibromyalgia, laser or placebo laser, sometimes alongside exercise. The 2025 umbrella rated fibromyalgia fatigue at moderate certainty (1.25, interval 0.63 to 1.87).
Against placebo laser, the pooled standardised mean differences were 1.16 on the Fibromyalgia Impact Questionnaire, 1.18 on pain, 1.01 on the tender-point count, and 1.4 on fatigue. When laser was added to a standard exercise program, that review found no extra symptom relief compared with exercise alone.
Device class in the evidence
Local laser, mostly on tender points.
What this does not show
That fibromyalgia is cured, that a whole-body bed was the device, or that light beats training. The trials are small and the settings differ. A moderate umbrella grade is not a high one.
06 · Mixed, local, or early
Who was studied
Hernandez-Bule and colleagues, a 2024 narrative review of photobiomodulation on skin. Maghfour and colleagues, a 21-expert consensus after a systematic search, Journal of the American Academy of Dermatology, 2025.
The consensus called photobiomodulation safe for adults in the uses it reviewed, and said red-light photobiomodulation does not induce DNA damage. It named peripheral neuropathy, androgenetic alopecia, wound ulcers of several causes, pressure ulcers, pain attributed to diabetic foot ulcers, and acute radiation dermatitis. One panelist sits on the advisory board of a light-device company (Omnilux). Another consults for laser companies. Those ties are in the paper.
Device class in the evidence
Local LED or laser on skin. A mask is a different fit from a contact laser.
What this does not show
That wrinkles reverse, that a home mask equals a studied contact laser, or that anti-aging is a measured lifespan outcome. A narrative skin review is not one trial with one number. The consensus summary used here is about adults.
07 · Mixed, local, or early
Who was studied
Ershadi and Barbieri, JAMA Dermatology, 2025. A systematic review and meta-analysis of 6 studies of at-home LED devices for acne vulgaris. One author disclosed consulting fees from other companies outside this paper.
The paper asks whether those home LED devices reduce acne lesions. The PubMed abstract does not print a pooled percent, so this page does not invent one. Blue light, used in acne because of bacteria, is not the red and near-infrared story sold for mitochondria.
Device class in the evidence
Face mask or small LED, often blue, red, or both. Not a whole-body bed.
What this does not show
That a red longevity panel treats acne, that blue light and red light are interchangeable, or that severe cystic acne is settled by six home-device studies.
08 · Mixed, local, or early
Who was studied
Huang and colleagues, 13 randomised trials, 413 people with diabetic foot ulcers. Laser was an add-on to wound care. The authors declared no conflicts.
Compared with control, laser was tied to a higher complete healing rate (risk ratio 2.10, interval 1.56 to 2.83), a smaller ulcer area, and a shorter healing time. The authors graded that evidence as very low and asked for larger, better trials before the parameters are settled.
Device class in the evidence
Local clinic laser or LED on the ulcer.
What this does not show
That a home panel is wound care. These were clinic trials on ulcers already under medical treatment. Very low certainty means the pooled ratio can move. It is not a reason to treat an open ulcer yourself.
09 · Mixed, local, or early
Who was studied
Vanin and colleagues reviewed photobiomodulation for performance and fatigue in healthy people. Pooled outcomes included time to exhaustion, repetitions, peak torque, and lactate. They rated the evidence very low to moderate.
The review found some effect in favor of light versus placebo, with lasers, LEDs, or both, mostly between 655 and 950 nm. Positive trials in that review often used about 20 to 60 joules on small muscle groups and 60 to 300 joules on large groups, with up to 200 milliwatts per diode. The trials are small, and both the exercise and the light settings vary.
Device class in the evidence
Local laser or LED cluster on the muscle that was exercised.
What this does not show
That a whole-body bed improves performance. That question has its own review, below, and it does not agree. It also does not show that those joules are your session, or that light replaces training.
10 · Mixed, local, or early
Who was studied
The 2025 umbrella rated one cognitive endpoint at moderate certainty (equivalent standardised mean difference 0.49, interval 0.14 to 0.84), inside a map where most endpoints were low or very low certainty. Zhu and colleagues, 2025, meta-analysed randomised trials of photobiomodulation and cognitive function.
Zhu reported gains in global cognition, working memory, and executive function in people with cognitive impairment, and partial gains in healthy adults. The authors said to treat that cautiously because the trials are heterogeneous and limited. They declared no financial interests.
Device class in the evidence
Transcranial near-infrared devices aimed at the head.
What this does not show
That Alzheimer's disease is reversed, that a consumer panel aimed at the chest delivers the light those head devices used, or that moderate certainty is high certainty. The umbrella authors said the wider field is not ready for widespread clinical adoption.
11 · Thin, null, or marketing ahead
Who was studied
Vital de Azevedo and colleagues pooled 5 randomised trials, 240 people, on the Pittsburgh Sleep Quality Index. One author is affiliated with a wellness center in Orlando. The authors declared no competing interests. Gimenez and colleagues ran a double-blind sham trial in adults with mild sleep complaints: morning near-infrared, four weeks, in summer and in winter.
The pooled questionnaire difference versus sham was about 1.25 points better (interval 0.11 to 2.38, p = 0.03). The authors call the evidence limited. In the Gimenez trial, 6.5 joules per square centimeter improved mood and drowsiness in winter only. Sleep and circadian measures did not change significantly. The funders had no role in that paper.
Device class in the evidence
Mixed. Local devices and some whole-body setups. Not one product.
What this does not show
That red light replaces sleep, fixes a body clock the way a drug might, or that a bed is a sleep treatment. A one point questionnaire move, with an interval that nearly touches zero, is a small signal.
12 · Thin, null, or marketing ahead
Who was studied
Alvarez-Martinez and Borden, 2025, a systematic review of whole-body photobiomodulation for exercise performance and recovery. Five studies. The authors declared no competing interests.
None of the five studies reported a benefit on biomarkers of fatigue or on exercise performance. Some sleep-related signals did appear: a subjective questionnaire, a commercial sleep tracker, higher serum melatonin, and a lower night-time heart rate in people using whole-body light.
Device class in the evidence
Whole-body bed, pod, or bay.
What this does not show
That a commercial bed raises performance or erases soreness the way some local muscle trials suggest. Local evidence does not transfer to a bed. The sleep signals are not a reason to skip sleep.
13 · Thin, null, or marketing ahead
Who was studied
Sun and colleagues, 11 randomised trials, 569 people. Photobiomodulation was pooled against a mix of exercise, diet changes, and sham light. The authors declared no competing interests.
The pooled differences included about 3.54 kg less weight, 1.18 less BMI, and 7.28 cm less waist. Fat-mass percent was not significant (difference about 0.28, p = 0.57). Waist-to-hip ratio and insulin were not clearly different either.
Device class in the evidence
Often a clinic laser aimed at the body. Not shown to match a consumer red panel.
What this does not show
That a red bed melts fat, that the weight change is fat, or that the result belongs to consumer red panels rather than the mix of devices, diets, and exercise in the pooling. Other contouring papers use different wavelengths, including green. That is a different device.
14 · Thin, null, or marketing ahead
Who was studied
Eghbaldoost and colleagues reviewed low-level laser and male infertility. The set is semen-sample studies plus one clinical trial of laser acupuncture. The authors declared no competing interests.
The sample studies reported a higher share of progressive sperm. The reviewers also say the studies differ too much to conclude that the laser on the sample is what caused it. The acupuncture trial reported better progressive motility without serious adverse effects in that report.
Device class in the evidence
Laboratory lasers on semen, or a research acupuncture setup. Not a bed.
What this does not show
A higher chance of a live birth, a treatment for female fertility, or a reason to use a consumer panel for fertility. Motility in a dish is not a pregnancy.
15 · Thin, null, or marketing ahead
Who was studied
Lourinho and colleagues, 2023, a systematic review and meta-analysis of controlled trials in adults with rheumatoid arthritis. The authors declared no competing interests.
The conclusion is that infrared laser may not be superior to sham in these patients. Pain and morning stiffness were among the outcomes without a clear infrared advantage. Evidence on red laser, laser acupuncture, and reflexology was too thin to support or refute.
Device class in the evidence
Local infrared laser in the trials that were pooled.
What this does not show
That rheumatoid arthritis and knee osteoarthritis are the same result. A positive knee-laser review does not cancel this one. It also does not show that a bed treats either condition.
16 · Thin, null, or marketing ahead
Who was studied
The widest map on this page is Son and colleagues, 2025: 15 meta-analyses, 204 randomised trials, over 9,000 participants, 35 endpoints, 15 conditions. The authors declared no competing interests.
Twelve outcomes were statistically significant in their re-pooling. Moderate certainty covered burning mouth pain, knee osteoarthritis disability, fibromyalgia fatigue, androgenetic alopecia hair density, and a cognitive measure. Most other endpoints were low or very low certainty. The authors say some conditions look useful, the overall certainty is low to moderate, and the field is not ready for widespread clinical adoption.
Device class in the evidence
Marketing usually means a bed or a large panel. The stronger records above are local devices.
What this does not show
A longer life, a lower biological age, or toxin clearance. There is no all-cause mortality trial of whole-body red light on this page, because this page did not find one to cite. A long reference list is not a grade.
The literature is noisy for ordinary reasons. Trials are often small. Devices are often the sponsor's device, so a result belongs to that geometry. Dose is reported badly, or reported in a way a home user cannot match. Sham devices are not all equally convincing. Pooling them into one 'red light works' sentence hides those differences.
Where two syntheses disagree, both stay on the page. Knee laser trials reduced pain against placebo. An updated rheumatoid arthritis review did not find infrared laser clearly better than sham. Local muscle reviews report some performance effects at very low to moderate certainty. A whole-body review of five studies reported none on performance or fatigue biomarkers. Neither side is deleted to make a cleaner ad.
A count of papers is not a grade. The 2025 umbrella started from 15 meta-analyses and 204 randomised trials and still called most endpoints low or very low certainty. Adding another brochure citation would make the list longer. It would not make the certainty higher.
Money sits close to several of the stronger documents. The hair trial used a named commercial comb. A dermatology consensus author advises a light-device brand, and another consults for laser companies. Two knee-review authors once sat on a laser-therapy society board and said they took no money from it. The neck-pain review reported no funding. Disclosed is not the same as disqualified, and undisclosed would be worse. The ties are part of the record.
The blocks above are the studies. The block below is a judgment about what to do with them. It has to say where it goes past the measurements.
Aaron Cuha’s position
This is opinion, not a finding. Everything else on this page is the evidence.
Red light has a few local human signals worth knowing. It is not a longevity cornerstone, and a whole-body bed is not the device those signals were measured on.
The reasoning
Where this goes beyond the evidence
Calling red light an adjunct after protein, training, and a blood panel is a priority judgment. No trial on this page randomised people to light versus those habits and counted years of life. There is also no all-cause mortality trial of a whole-body bed here. The hair, knee, and neck numbers were measured with combs and clinic lasers, not with the device a studio sells as anti-aging. Treating adjunct as a mild yes still goes past the evidence, because adjunct means it adds something on top of the floor, and that addition was not the experiment. Biphasic curves in cells and animals mean a brighter panel is not obviously a better one, and this page still cannot tell you the joules your tissue received. If the nulls are what generalise to consumer beds, and the positive local trials do not, then the claim that local signals are ahead is the part that was early.
Who this is not for
Anyone pregnant, anyone on a photosensitizing drug who has not asked a clinician, anyone who would aim a home device at a known cancer, anyone with photosensitive epilepsy around flickering light, and anyone who wants this page to replace a diagnosis or to hand them a personal session plan.
Aaron Cuha, who built this archive and reads the studies behind the pages. He is a coach, not a doctor, and no medical credential is claimed for him anywhere on this site. More about who writes this
Instead of a diagnosis
Pain, a wound, hair loss, and a mouth sore can each be something a clinician needs to see. A panel is not that visit.
Pregnancy
The studies cited here do not establish safety in pregnancy. This page does not recommend red light in pregnancy.
Photosensitizing drugs and photodermatoses
The dermatology consensus called red-light photobiomodulation safe for adults in the uses it reviewed. That is not a clearance for every drug. If you take a photosensitizing medicine, ask a clinician. This page is not that clinician.
A known cancer in the beam
Do not aim a consumer device at a known tumor. The oncology papers are about preventing mouth sores from cancer treatment, with exact clinician settings. They are not a home treatment for cancer.
Flicker and photosensitive epilepsy
Flickering visible light can trigger seizures in some people with photosensitive epilepsy. A panel that pulses is a different situation from a steady clinical beam. Ask a clinician if that is you. This page is not a seizure study.
Anyone wanting a personal session plan
Joules, minutes, and weekly calendars on this page are records of what a trial ran. They are not instructions for your body.
Near-infrared is invisible, so brightness is a bad safety check. Do not stare into emitters. Follow the eyewear instructions for that device. This page does not have a consumer-panel retinal dose limit to quote as a number.
The hair-comb trials reported no serious adverse events. The neck-pain review found mild effects no different from placebo. That is not a promise for every high-output bed. If a device hurts, burns, or leaves a strong redness, stop and get it looked at. Photobiomodulation in these papers is non-heating light.
The dermatology consensus summary used here is about adults. This page does not make a recommendation for children.
Establishment registration means a firm told the FDA it makes or imports devices. That is paperwork. It is not a finding that a device works. A 510(k) clearance, when one exists, means the FDA accepted substantial equivalence to an earlier device for a named use. The comb trial describes an FDA-cleared comb. Clearance is not a drug approval, and it does not move to a different device or a different claim. Medical grade is a sales phrase. It is not an FDA grade of efficacy.
This site teaches a blood panel, protein, and training before gadgets. Red light does not move that order. If the floor is missing, a panel does not replace it.
Nothing on this page is for sale. No seller wrote it. A later page could discuss device makers against the criteria below. This version does not.
Educational use only. This page is not medical advice, not a treatment protocol, and not a personal session plan. Numbers from trials are what a study ran, not a dose for you. MASCC, ISOO, and WALT documents are references for clinicians. They are not do-it-yourself schedules. Aaron Cuha is a coach, not a doctor.
Six classes. No brand is ranked, and no maker is listed. A separate makers page is deferred. The private notes that compare companies stay off this page.
Class 01
A contact or near-contact laser, usually in a clinic, with a named wavelength, spot size, and energy per spot. Often the device in the knee, neck, wound, and mouth-sore trials.
Evidence match. Closest match when the goal is one of those trial settings and a clinician is running the parameters.
Mismatch. Not a consumer panel at a distance. Not a wellness bed. Class of laser is a safety label, not a proof of benefit.
Class 02
A flat array of red and near-infrared LEDs used at a stated distance, often several inches to a couple of feet.
Evidence match. A delivery method. It is photobiomodulation only if the spectrum and the irradiance at that distance are known.
Mismatch. Most of the stronger trials did not use this geometry. Irradiance falls as you step back. A wattage slogan does not fix that.
Class 03
A contoured LED worn on the face, sometimes red, sometimes with blue or amber.
Evidence match. The form factor in some cosmetic and acne studies. Blue acne lamps are a different mechanism from red and near-infrared.
Mismatch. Fit gaps change the dose. A mask is not a clinic laser and not a mucositis protocol. Emitters sit near the eyes.
Class 04
Emitters held against or just off the scalp. This is the form factor in the pattern-hair trials and in many clearance claims for androgenetic alopecia.
Evidence match. The stronger hair evidence lives here, and it is device specific. A cleared comb is a named use, not a general wellness license.
Mismatch. A helmet is not a brain trial unless the trial aimed light at the head and measured cognition. Hair evidence does not become athletic recovery or longevity.
Class 05
A canopy, bed, or bay that surrounds a large skin area. Common in studios.
Evidence match. A way to expose a lot of skin at once. Exposure is not the same thing as the dose in a spot trial.
Mismatch. The whole-body performance review did not find an exercise benefit. A bed is not a MASCC mouth-sore protocol. Heat, claustrophobia, and eye exposure are separate from the mitochondrial story.
Class 06
Lamps outside red and near-infrared. Blue shows up in acne. Green shows up in some contouring lasers.
Evidence match. Only the trials that actually used that color, for that goal.
Mismatch. They are not the mitochondrial red-light hypothesis, and they are not interchangeable with the red and near-infrared trials above.
The fifth and sixth items rest on the home-device pilot (PMID 39996950) and on the guideline mismatch above. They are criteria, not a score, and not a link to a shop.
Floor habits and the existing map. None of these is a cart.
Order
The sequence. Measure first. Floor habits before gadgets.
Start
A way in that does not begin with a device.
Floor
What has been measured about strength. Light does not replace it.
Floor
The intake results, with the population on each one.
Floor
A marker, or a panel you still need. Not a diagnosis.
Map
The existing pillars. Red light is not one of them on that map yet.
Knowledge stays free. No seller wrote this page. Every source below opens the PubMed record that was checked before the sentence was written.
Educational use only. This page is not medical advice, not a treatment protocol, and not a personal session plan. Numbers from trials are what a study ran, not a dose for you. MASCC, ISOO, and WALT documents are references for clinicians. They are not do-it-yourself schedules. Aaron Cuha is a coach, not a doctor.
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.